FIA
AUPH icon

FNY Investment Advisers’s Aurinia Pharmaceuticals AUPH Stock Holding History

FNY Investment Advisers’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,500
Closed -$43K – 607
2023
Q2 		$43K Buy
4,500
+3,000
+200% +$31.1K 0.05% 177
2023
Q1 		$16K Buy
+1,500
New +$13.2K 0.02% 290

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FNY Investment Advisers's AUPH Position: Q3 2023 in Review

FNY Investment Advisers sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2023, closing a stake of 4,500 shares — an estimated $43K sold.

FNY Investment Advisers first reported a position in AUPH in Q1 2023 and held it in 2 quarters. The position peaked at $43K in Q2 2023. 198 funds tracked by Wall St. Rank hold AUPH as of Q3 2023.

  • FNY Investment Advisers reported no remaining Aurinia Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • FNY Investment Advisers sold 4,500 Aurinia Pharmaceuticals shares in Q3 2023, an estimated $43K.
  • FNY Investment Advisers first reported a position in Aurinia Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • FNY Investment Advisers's Aurinia Pharmaceuticals position peaked at $43K in Q2 2023.
  • 198 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2023.

Based on FNY Investment Advisers's 13F filing for Q3 2023, filed 10 Oct 2023.